India Markets closed

Buy, Sell, Hold: 6 stocks are being tracked by analysts on March 28, 2018

Uttaresh Venkateshwaran
1 / 1

Friday’s rally on Nifty might have caught the bears on the wrong foot; 3 stocks to buy

Friday’s move again brought the indices into the erstwhile trading range. Hence, sustaining above 10,700 kind of levels markets may once again remain sideways and volatile without any price damage.

Moneycontrol News


Brokerage: Credit Suisse | Rating: Outperform | Target: Cut to Rs 175

The global research firm said that Q4 may reflect partial recovery. It sees 30% higher employee costs seem to be absorbed even as 9MFY18 margin is higher YoY. It is revising earnings estimates by 6 and 4 percent for FY18 and FY19, respectively.

Persistent Systems

Brokerage: Credit Suisse | Rating: Outperform | Target: Rs 960

Credit Suisse believes that its Q4 may be weak but medium-term story is intact. IP is a volatile element of the company’s business and hence can create nuances. It also continues to expect healthy revenue growth.

Brokerage: Morgan Stanley | Rating: Overweight | Target: Rs 1,025

The global brokerage firm said that the guidance for decline in IP revenue in Q4 has come as a negative surprise. It sees a potential 6% cut to FY18 EPS as most likely outcome.

ICICI Lombard

Brokerage: CLSA | Rating: Buy | Target: Rs 970

Over FY17-20, it sees 24% earnings CAGR led by premium growth & margin expansion. It expects the company to benefit from regulatory actions with the change in motor TP norms.

Motherson Sumi

Brokerage: Credit Suisse | Rating: Outperform | Target: Rs 440

The firm said that BS-VI implementation is likely to provide a big boost to wiring harness industry. It highlighted that the company is not too worried about topline slowdown at SMR and that it will return soon. For SMP, the margin can remain under pressure for few quarters as 2 large plants come on stream. It believes recent correction represents a good entry opportunity.

GSK Consumer

Brokerage: CLSA | Rating: Buy | Target: Rs 7,850

The brokerage said that acquisition of Novartis’ stake may lead to divestment of GSK Consumer. A change in ownership may increase focus & improve its growth trajectory. It added that the deal value will depend on distribution alliance.

M&M Fin

Brokerage: Deutsche Bank | Rating: Buy | Target: Rs 550

Recovery seems broad-based, with multiple growth drivers, it said, adding that the company has increased focus on CVs and used vehicles. Improving rural trends should result in better asset quality, it added.